MeSH term
Frequency | Condition_Probility | Adolescent | 50 | 0.0 |
Child | 52 | 0.0 |
Child, Preschool | 31 | 0.0 |
*Electroretinography | 37 | 86.0 |
Female | 86 | 0.0 |
Humans | 174 | 0.0 |
Male | 95 | 0.0 |
Photoreceptors, Vertebrate/*physiology | 5 | 50.0 |
Adult | 75 | 0.0 |
*Evoked Potentials, Visual | 5 | 17.0 |
Fundus Oculi | 12 | 13.0 |
Middle Aged | 60 | 0.0 |
Pedigree | 15 | 0.0 |
Photic Stimulation/methods | 2 | 8.0 |
Reaction Time | 8 | 7.0 |
Research Support, Non-U.S. Gov't | 101 | 0.0 |
Retina/physiopathology | 4 | 50.0 |
Visual Acuity | 9 | 5.0 |
Adaptation, Ocular | 2 | 50.0 |
Case-Control Studies | 7 | 0.0 |
Comparative Study | 21 | 0.0 |
Cones (Retina)/physiopathology | 2 | 40.0 |
Dark Adaptation | 22 | 56.0 |
*Linkage (Genetics) | 7 | 0.0 |
Night Blindness/genetics/*physiopathology | 2 | 100.0 |
Photic Stimulation | 13 | 20.0 |
Retina/*physiopathology | 18 | 72.0 |
Rods (Retina)/physiopathology | 2 | 28.0 |
Amino Acid Sequence | 20 | 0.0 |
Animals | 47 | 0.0 |
Base Sequence | 25 | 0.0 |
Chromosome Mapping | 5 | 0.0 |
DNA Primers | 6 | 0.0 |
Molecular Sequence Data | 29 | 0.0 |
*Mutation | 5 | 0.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
Retina/*physiology | 8 | 44.0 |
Sequence Alignment | 6 | 0.0 |
Sequence Deletion | 4 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
X Chromosome | 4 | 0.0 |
Aged | 29 | 0.0 |
DNA Mutational Analysis | 6 | 0.0 |
Deoxyribonucleases, Type II Site-Specific/genetics | 2 | 4.0 |
Japan | 2 | 0.0 |
Prognosis | 9 | 0.0 |
Sex Factors | 3 | 0.0 |
Electroretinography | 47 | 26.0 |
Retinal Diseases/*diagnosis/physiopathology | 2 | 66.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 10 | 0.0 |
Tumor Cells, Cultured | 8 | 0.0 |
DNA-Binding Proteins/genetics | 4 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Proto-Oncogene Proteins/genetics | 3 | 0.0 |
RNA, Messenger/genetics | 5 | 0.0 |
Trans-Activators/genetics | 4 | 1.0 |
Transcription Factors/genetics/*physiology | 2 | 1.0 |
Action Potentials/drug effects/physiology | 2 | 15.0 |
Anti-Arrhythmia Agents/pharmacology | 5 | 27.0 |
Calcium Channel Blockers/pharmacology | 2 | 2.0 |
*Cation Transport Proteins | 15 | 6.0 |
Cell Line | 6 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
*Membrane Transport Proteins | 4 | 0.0 |
Models, Neurological | 2 | 1.0 |
Patch-Clamp Techniques | 5 | 1.0 |
*Potassium Channels, Voltage-Gated | 17 | 6.0 |
Rats | 13 | 0.0 |
Dogs | 3 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Phenotype | 10 | 0.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Translocation, Genetic | 7 | 0.0 |
Conjunctiva/ultrastructure | 2 | 50.0 |
Disease Progression | 2 | 0.0 |
Follow-Up Studies | 4 | 0.0 |
Polymerase Chain Reaction | 9 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Interneurons/physiology | 2 | 66.0 |
Photoreceptors, Vertebrate/physiology | 2 | 25.0 |
Analysis of Variance | 2 | 0.0 |
Color Perception/physiology | 2 | 25.0 |
Electroretinography/methods | 3 | 50.0 |
Genotype | 7 | 0.0 |
Linkage (Genetics) | 5 | 0.0 |
Psychophysics | 4 | 15.0 |
Research Support, U.S. Gov't, P.H.S. | 34 | 0.0 |
Retinal Degeneration/genetics/*physiopathology | 2 | 50.0 |
Blotting, Western | 4 | 0.0 |
*DNA-Binding Proteins | 13 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
RNA, Messenger/analysis | 5 | 0.0 |
*Trans-Activators | 15 | 2.0 |
*Transcription Factors | 6 | 0.0 |
Rods (Retina)/*physiology | 2 | 50.0 |
*X Chromosome | 7 | 0.0 |
Carrier Proteins/*genetics | 3 | 0.0 |
DNA Primers/chemistry | 4 | 0.0 |
*Eye Proteins | 3 | 1.0 |
Fluorescein Angiography | 9 | 7.0 |
*Gene Deletion | 2 | 0.0 |
Linkage (Genetics)/genetics | 2 | 0.0 |
X Chromosome/*genetics | 3 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Immunohistochemistry | 5 | 0.0 |
Mice | 17 | 0.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Incidence | 2 | 0.0 |
Retrospective Studies | 5 | 0.0 |
Potassium Channels/genetics | 2 | 4.0 |
*Proto-Oncogene Proteins | 4 | 0.0 |
RNA-Binding Protein EWS | 4 | 14.0 |
Electroretinography/*methods | 8 | 100.0 |
Calcium Channels, L-Type/metabolism | 2 | 20.0 |
Cell Separation | 2 | 0.0 |
In Vitro | 3 | 0.0 |
Myocardium/cytology/metabolism | 2 | 7.0 |
Organ Specificity | 2 | 0.0 |
Phenethylamines/pharmacology | 3 | 21.0 |
Potassium Channel Blockers | 3 | 11.0 |
Potassium Channels/metabolism | 2 | 5.0 |
Sulfonamides/pharmacology | 3 | 2.0 |
Proto-Oncogene Proteins/*physiology | 2 | 0.0 |
Transcription Factors/*physiology | 4 | 0.0 |
Cells, Cultured | 7 | 0.0 |
DNA-Binding Proteins/*genetics | 3 | 0.0 |
Trans-Activators/*genetics | 2 | 0.0 |
Blotting, Southern | 4 | 0.0 |
*Chromosome Mapping | 3 | 0.0 |
Chromosomes, Human, Pair 21 | 3 | 2.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
Infant | 19 | 0.0 |
Karyotyping | 4 | 0.0 |
Pregnancy | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 4 | 0.0 |
Binding Sites | 4 | 0.0 |
Dimerization | 2 | 0.0 |
Models, Molecular | 2 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Protein Conformation | 2 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Age of Onset | 3 | 0.0 |
Electrooculography | 6 | 14.0 |
*Fundus Oculi | 2 | 25.0 |
Potassium Channels/genetics/*physiology | 2 | 18.0 |
Rabbits | 3 | 0.0 |
Time Factors | 5 | 0.0 |
Xenopus | 3 | 0.0 |
Cattle | 2 | 0.0 |
*Lipoproteins | 2 | 5.0 |
*Nerve Tissue Proteins | 2 | 0.0 |
Phosphorylation | 3 | 0.0 |
Rhodopsin/metabolism | 2 | 14.0 |
Diabetic Retinopathy/diagnosis/*physiopathology | 2 | 100.0 |
Visual Fields | 7 | 11.0 |
Visual Pathways/physiopathology | 2 | 100.0 |
Alleles | 3 | 0.0 |
Electrophysiology | 5 | 1.0 |
Evoked Potentials, Visual/physiology | 2 | 18.0 |
Cones (Retina)/*physiopathology | 2 | 50.0 |
Treatment Outcome | 2 | 0.0 |
Diagnosis, Differential | 7 | 0.0 |
Infant, Newborn | 7 | 0.0 |
Magnetic Resonance Imaging | 3 | 0.0 |
Retina/pathology/*physiopathology | 2 | 50.0 |
Chromosomes, Human, Pair 22 | 3 | 1.0 |
Oncogene Proteins, Fusion/*genetics | 7 | 3.0 |
*Repressor Proteins | 5 | 0.0 |
DNA/analysis | 3 | 0.0 |
Eye Proteins/*genetics | 2 | 1.0 |
Retinal Degeneration/*genetics/physiopathology | 2 | 40.0 |
Severity of Illness Index | 2 | 0.0 |
English Abstract | 20 | 0.0 |
Retinal Diseases/*diagnosis | 2 | 40.0 |
*Phenotype | 2 | 0.0 |
Oligonucleotide Probes | 2 | 0.0 |
Piperidines/pharmacology | 4 | 6.0 |
Pyridines/pharmacology | 4 | 1.0 |
Rats, Wistar | 2 | 0.0 |
DNA/metabolism | 2 | 0.0 |
*Morphogenesis | 2 | 10.0 |
Mutation | 5 | 0.0 |
*Neovascularization, Physiologic | 2 | 1.0 |
Transfection | 4 | 0.0 |
Alternative Splicing | 2 | 0.0 |
Heterogeneous-Nuclear Ribonucleoproteins | 4 | 3.0 |
Leukemia, Myeloid/*genetics | 2 | 1.0 |
Precipitin Tests | 3 | 0.0 |
Protein Binding | 2 | 0.0 |
RNA-Binding Protein FUS | 2 | 10.0 |
3T3 Cells | 2 | 0.0 |
Bone Neoplasms/*genetics | 4 | 9.0 |
Gene Expression Regulation | 3 | 0.0 |
Oncogene Proteins/genetics | 3 | 4.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Sarcoma, Ewing's/*genetics | 8 | 17.0 |
Transcription Factors/genetics | 2 | 0.0 |
Transcription, Genetic | 10 | 0.0 |
Gene Expression | 5 | 0.0 |
Transcription Factors/*genetics | 6 | 0.0 |
Genes, Recessive | 3 | 0.0 |
Retinitis Pigmentosa/*genetics/physiopathology | 2 | 16.0 |
Visual Fields/*physiology | 2 | 25.0 |
Reference Values | 5 | 0.0 |
Sensory Thresholds | 2 | 12.0 |
Aminobutyric Acids/pharmacology | 2 | 66.0 |
Macaca mulatta | 3 | 0.0 |
Electroretinography/drug effects | 2 | 66.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Perimetry | 3 | 10.0 |
Antigens, CD/*genetics | 2 | 0.0 |
Cell Adhesion Molecules/*genetics | 2 | 2.0 |
DNA | 3 | 0.0 |
Down-Regulation/genetics | 2 | 3.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
*Response Elements | 2 | 3.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*genetics | 2 | 0.0 |
*Immediate-Early Proteins | 4 | 1.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
Transcription Factors/*metabolism | 3 | 0.0 |
Potassium Channels/*genetics/metabolism | 2 | 7.0 |
Cloning, Molecular | 6 | 0.0 |
Mice, SCID | 2 | 0.0 |
Transcription Factors/genetics/*metabolism | 2 | 0.0 |
Macular Degeneration/*physiopathology | 2 | 100.0 |
Dystrophin/*genetics | 2 | 8.0 |
*Heterozygote Detection | 4 | 3.0 |
Muscular Dystrophies/*genetics/physiopathology | 2 | 66.0 |
Membrane Potentials/physiology | 2 | 2.0 |
Models, Biological | 2 | 0.0 |
Plasmids | 3 | 0.0 |
Prospective Studies | 4 | 0.0 |
Gene Deletion | 2 | 0.0 |
Muscular Dystrophies/genetics/*physiopathology | 2 | 66.0 |
Photoreceptors/physiology | 3 | 42.0 |
Sensitivity and Specificity | 3 | 0.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
Species Specificity | 2 | 0.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Binding Sites/genetics | 2 | 0.0 |
Multigene Family | 3 | 0.0 |
*Oncogenes | 4 | 0.0 |
Acute Disease | 3 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Ribonucleoproteins/*genetics | 2 | 4.0 |
Retina/*drug effects/physiopathology | 2 | 100.0 |
Mice, Mutant Strains | 2 | 0.0 |
*Translocation, Genetic | 4 | 0.0 |
Blotting, Northern | 2 | 0.0 |
*Chromosomes, Human, Pair 21 | 6 | 3.0 |
Restriction Mapping | 4 | 0.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
RNA-Directed DNA Polymerase | 2 | 1.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Ophthalmoscopy | 2 | 8.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
Age Factors | 5 | 0.0 |
*Macula Lutea | 2 | 40.0 |
Genetic Markers | 2 | 0.0 |
*Genes, Dominant | 2 | 0.0 |
Translocation, Genetic/*genetics | 2 | 0.0 |
Light | 6 | 2.0 |
Brain/*abnormalities/pathology/physiopathology | 2 | 50.0 |
Optic Nerve/*abnormalities/pathology/physiopathology | 2 | 100.0 |
Photoreceptors/physiopathology | 6 | 100.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Exons | 3 | 0.0 |
RNA Splicing | 2 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
*Electroretinography/methods | 4 | 80.0 |
*Chromosomes, Human, Pair 22 | 2 | 0.0 |
*Genes | 2 | 0.0 |
Retinal Degeneration/physiopathology | 2 | 66.0 |
Chromosome Deletion | 2 | 0.0 |
Pigment Epithelium of Eye/physiopathology | 2 | 50.0 |
Photometry | 2 | 12.0 |
Retroviridae Proteins, Oncogenic/*genetics | 2 | 9.0 |
Photoreceptors/*physiopathology | 3 | 75.0 |
Retinitis Pigmentosa/*physiopathology | 3 | 75.0 |
Retinal Diseases/diagnosis | 2 | 40.0 |
Electroretinography/instrumentation/*methods | 2 | 100.0 |
Cats | 2 | 0.0 |
Color Perception | 2 | 28.0 |
Disease Models, Animal | 2 | 0.0 |
Retinal Diseases/*physiopathology | 2 | 50.0 |
Mathematics | 2 | 1.0 |
Heterozygote | 2 | 0.0 |
Chronic Disease | 3 | 0.0 |
